A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients
NCT03709628
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
8
Enrollment
INDUSTRY
Sponsor class
Conditions
Crohn Disease
Interventions
DRUG:
EB8018 (First-in-class FimH blocker)
Sponsor
Enterome